Gainers

• Alaunos Therapeutics (NASDAQ:TCRT) shares rose 20.5% to $3.65 during Tuesday's after-market session. The market value of their outstanding shares is at $2.6 million.
• Circle8 Group (NASDAQ:CIRC) stock moved upwards by 15.12% to $0.42. The market value of their outstanding shares is at $52.6 million.
• Brookdale Senior Living (NYSE:BKD) stock increased by 9.48% to $11.08. The market value of their outstanding shares is at $2.4 billion.
• FibroBiologics (NASDAQ:FBLG) stock rose 8.63% to $1.04. The company's market cap stands at $7.0 million.
• Niki BioSolutions (NASDAQ:NIKI) stock moved upwards by 8.19% to $2.84. The market value of their outstanding shares is at $2.4 million.
• TuHURA Biosciences (NASDAQ:HURA) shares moved upwards by 6.83% to $1.93. The company's market cap stands at $121.0 million.

Losers

• Biomea Fusion (NASDAQ:BMEA) stock decreased by 23.8% to $0.96 during Tuesday's after-market session. The market value of their outstanding shares is at $98.5 million.
• Pomdoctor (NASDAQ:POM) shares fell 21.69% to $0.57. The market value of their outstanding shares is at $5.7 million.
• NeuroSense Therapeutics (NASDAQ:NRSN) shares declined by 17.48% to $2.88. The market value of their outstanding shares is at $6.6 million.
• Mettler-Toledo Intl (NYSE:MTD) stock decreased by 14.84% to $1361.01. The market value of their outstanding shares is at $31.6 billion.
• Picard Medical (AMEX:PMI) shares decreased by 10.05% to $13.79. The company's market cap stands at $23.2 million.
• Mobile-health Network (NASDAQ:MNDR) shares declined by 8.91% to $1.33. The company's market cap stands at $3.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.